| Literature DB >> 18299743 |
Alexander Yavorskyy1, Aaron Hernandez-Santana, Geraldine McCarthy, Gillian McMahon.
Abstract
Clinically, osteoarthritis (OA) is characterised by joint pain, stiffness after immobility, limitation of movement and, in many cases, the presence of basic calcium phosphate (BCP) crystals in the joint fluid. The detection of BCP crystals in the synovial fluid of patients with OA is fraught with challenges due to the submicroscopic size of BCP, the complex nature of the matrix in which they are found and the fact that other crystals can co-exist with them in cases of mixed pathology. Routine analysis of joint crystals still relies almost exclusively on the use of optical microscopy, which has limited applicability for BCP crystal identification due to limited resolution and the inherent subjectivity of the technique. The purpose of this Critical Review is to present an overview of some of the main analytical tools employed in the detection of BCP to date and the potential of emerging technologies such as atomic force microscopy (AFM) and Raman microspectroscopy for this purpose.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18299743 PMCID: PMC2625400 DOI: 10.1039/b716791a
Source DB: PubMed Journal: Analyst ISSN: 0003-2654 Impact factor: 4.616
Fig. 1A joint with severe osteoarthritis. In osteoarthritis, the cartilage becomes worn away. Spurs grow out from the edge of the bone, and synovial fluid increases. Altogether, the joint feels stiff and sore.
Common crystal-associated arthropathies
| Crystals | Appearance | Size | Conditions |
| Basic calcium phosphate (BCP) | Clumps and globules. | 1 nm
| Osteoarthritis. |
| Amorphous-looking. | 5–20 µm (clumps)
| Milwaukee shoulder–knee syndrome. | |
| Appear as ‘shiny coins’ when clumped. | Periarthritis/tendonitis | ||
| Non-birefringent | |||
| Calcium pyrophosphate dihydrate (CPPD) | Rod- or rhomboidal-shaped. | 1–20 µm
| Pseudogout. |
| Weakly positively birefringent | CPPD deposition disease | ||
| Monosodium urate (MSU) | Needle-shaped. | 2–30 µm
| Acute/chronic gout |
| Frequently intracellular. | |||
| Strongly negatively birefringent | |||
| Calcium oxalate (CO) | Tetragonal, bipyramidal, octahedral or envelope shape | 15–20 µm
| Calcium oxalate-associated arthritis |
Composition of synovial fluid relative to other human bodily fluids (modified from refs 54 and 55)
| Test | Synovial fluid | Plasma | Sweat | Saliva | Semen |
| pH | 7.4 | 7.35–7.45 | 4–6.8 | 6.4 | 7.19 |
| Specific gravity | 1.008–1.015 | 1.0278
| 1.001–1.008 | 1.007 | 1.028 |
| Electrolytes/mEq l–1 | |||||
| Potassium | 4.0 | 3.5–5.0 | 4.3–14.2 | 21 | 31.3 |
| Sodium | 136.1 | 135–147 | 0–104 | 14 | 117 |
| Calcium | 2.3–4.7 | 8–11 | 0.2–6.0 | 3 | 12.4 |
| Magnesium | 1.5–2.5 | 0.03–4 | 0.6 | 11.5 | |
| Bicarbonate | 19.3–30.6 | 95–105 | 6 | 24 | |
| Chloride | 107.1 | 22–28 | 34.3 | 17 | 42.8 |
| Proteins/mg dl–1 | |||||
| Total | 1.72 g dl–1 | 6–8 g dl–1 | 7.7 | 386 | 4.5 g dl–1 |
| Albumin | 55–70% | 50–65% | |||
| Alpha-1-globulin | 6–8% | 3–5% | |||
| Alpha-2-globulin | 5–7% | 7–13% | |||
| Beta-globulin | 8–10% | 8–14% | |||
| Gamma-globulin | 10–14% | 12–22% | |||
| Hyaluronic acid | 0.3–0.4 g dl–1 | ||||
| Metabolites/mg dl–1 | |||||
| Amino acids | 47.6 | 40 | 1.26 g dl–1 | ||
| Glucose | 70–110 | 70–110 | 3.0 | 11 | 224 |
| Uric acid | 2–8 | 2–8 | 26–122 | 20 | 72 |
| Lipids, total | 25–500 | 188 | |||
Increases under salivary stimulation.
Primary alpha-amilase, with some lysozomes.
Fructose caption.
Not present in eccrine secretions.
Cholesterol.
Some properties of hydroxyapatite and its precursors (adapted from refs 63–66)
| Type of BCP | Formula | Molar ratio Ca : P | P content of crystals/mmol g–1 | Solubility product constant, | Calcium conc. at equilibrium/mol |
| Hydroxyapatite (HA) | Ca10(PO4)6(OH)2 | 1.67 : 1 | 5970 | 2.34 × 10–59 | 4.36 × 10–7 |
| = Ca5(PO4)3OH | |||||
| = 3Ca3(PO4)2·Ca(OH)2 | |||||
| Tricalcium phosphate | Ca3(PO4)2 | 1.50 : 1 | 6450 | 2.83 × 10–30 | 1.45 × 10–6 |
| Octacalcium phosphate | Ca8(HPO4)2(PO4)4·5H2O | 1.33 : 1 | 6000 | 2.00 × 10–49 | 1.08 × 10–6 |
| = Ca4H(PO4)3·3H2O |
Analytical methods that have been used for BCP detection
| Technique | Advantages | Disadvantages |
| Imaging methods | ||
| Light and polarised microscopy | Inexpensive, widely available and useful for the larger crystals (>1 µm) that can occur | Inaccurate, non-specific and cannot detect BCP crystals. Polarised microscopy can aid detection of MSU and CPPD |
| Microscopy with staining | Inexpensive, widely available and can identify BCP crystal clumps | Sensitive but non-specific, false positive results are frequent. |
| One dye is not enough to distinguish between the different types of crystals | ||
| Multi-dimensional microscopy | Coupling of multi-channel micro-spectrophotometer and 3-D relief imaging system to a microscope laser light scattering spectroscope | Not widely available. No evidence of clear identification of synovial fluid crystals |
| Transmission electron microscopy | Small sample size and can be used with electron diffraction | Expensive, complex, not widely available, operator-dependent |
| Scanning electron microscopy | Small sample size and can be coupled to X-ray elemental analysis | Expensive, complex, relies on morphology |
| Atomic force microscopy | Small sample size, minimal sample preparation. Can exploit hardness and lattice features in sample for detection and identification. Chemical force microscopy may offer more specificity | Operator-dependent, intricate to use on liquid samples, relies on morphology to an extent |
| Spectroscopic methods | ||
| FTIR | Accurate, used for automated pattern recognition methods | Can be misinterpreted and water interferes in certain parts of the spectrum |
| Raman | Accurate, water does not interfere, unique spectral signatures for each crystal type | Expensive, fewer library spectra available. Sample purification required to distinguish between various crystal types |
| Fluorescence | With correct dyes, can be very sensitive and selective | Requires special equipment; dyes can be expensive, not suitable for |
| NMR/MRI | Can visualise most types of pathologies including crystal depositions | Very expensive, cannot identify nature of crystal deposition. Operator-dependent |
| Other methods | ||
| Calcium and phosphorus analysis | Well-understood assays such as atomic spectrometry, UV-Vis spectrophotometry, | Practical only in analysis of dissociated crystals, other matter present in the fluid can interfere |
| X-Ray diffraction | Accurate technique for unambiguous identification | Requires sample to be pure, dried and in sufficient quantity |
| Capillary electrophoresis | Can be used for pattern recognition analysis of synovial fluids containing crystals | Not applicable for direct separation of crystals |
| Radioassay | Allows semi-quantitative determination of BCP crystals | Involves radioactive reagents |
| Ferrography | Provides separation of particles by size/magnetic properties | Requires special sample preparation, only reflects general content of particles in synovial fluid |
Fig. 2A group of negatively birefringent monosodium urate (MSU) crystals aspirated from a tophus (magnification × 1400, original magnification × 400). Reproduced with permission from ref. 91. (Copyright 1992, Ciba-Geigy Corp.)
Fig. 3Calcium pyrophosphate dihydrate (CPPD) crystals extracted from the synovial fluid of a patient with pseudogout viewed under polarised light microscopy. Note the fact that some of the particles do not appear to exhibit birefringence. Reproduced with permission from ref. 75. (Copyright 1999, BMJ Publishing Group Ltd.)
Fig. 4Typical calcium oxalate (CO) crystals obtained from a synovial fluid effusion in a patient on long-term dialysis (magnification × 1800, original magnification × 400). Reproduced with permission from ref. 94. (Copyright 1992, Ciba-Geigy Corp.)
Fig. 5A synovial fluid wet smear stained with Alizarin red S. The darker red deposits have the appearance of hydroxyapatitc accumulations. The specimen is from a patient with end-stage renal disease (magnification × 720, original magnification × 200). Reproduced with permission from ref. 94. (Copyright 1992, Ciba-Geigy Corp.)
Fig. 6Micrographs of solid particles in the synovial fluids of normal (a), osteoarthritis (b), and traumatic synovitis (c) subjects. Reproduced with permission from ref. 104. (Copyright 2007, Elsevier Ltd.)
Fig. 7AFM images of HA and CPPD crystals from a patient with HA-induced arthritis. (A) HA crystals clump to form pseudospherical microaggregates (100–150 nm in diameter). (B) CPPD crystals shown here were an unexpected finding in this specimen. Reproduced with permission from ref. 122. (Copyright 1995, Elsevier Ltd.)
Fig. 8Infrared spectrum of hydroxyapatite. Reproduced with permission from ref. 127. (Copyright 2007, Elsevier Ltd.)
Fig. 9Caption typical infrared spectra of synovial joint fluid. Reproduced with permission from ref. 124. (Copyright 2004, IEEE.)
Fig. 10Infrared difference spectra generated by the subtraction of the class-average spectrum of non-arthritic synovial fluid films from the class-average spectra of synovial fluid films for (1) osteoarthritis (2) rheumatoid arthritis and (3) spondyloarthropathy. Reproduced with permission from ref. 128. (Copyright 1997, John Wiley & Sons, Inc.)
Fig. 11IR spectra of osteoarthritis and rheumatoid arthritis synovial fluid samples. Both are transmission spectra in the range of 2500 to 2000 cm–1. A reference spectrum of water was subtracted from each sample. Bands at 2362 and 2340 cm–1 result from CO2 vibrations. Reproduced with permission from ref. 129. (Copyright 2002, Elsevier Ltd.)
Fig. 12Raman reference spectra of synthetic BCP, HA, CPPD and MSU crystals.
Fig. 13Pamidronate-IRDye78.
Fig. 14Capillary electropherograms of human synovial fluid: (a) normal sample; (b) osteoarthritis; (c) rheumatoid arthritis. A and B: unidentified substances; C: presumably hyaluronan, D: uric acid. Reproduced with permission from ref. 174. (Copyright 1994, Royal Society of Chemistry.)